05438nam 2201441z- 450 991059507290332120230220(CKB)5680000000080797(oapen)https://directory.doabooks.org/handle/20.500.12854/92141(oapen)doab97480(EXLCZ)99568000000008079720202209d2022 |y 0engurmn|---annantxtrdacontentcrdamediacrrdacarrierClinical Utility of Applying PGx and Deprescribing-Based Decision Support in PolypharmacyFuture PerspectivesBaselMDPI - Multidisciplinary Digital Publishing Institute20221 online resource (224 p.)3-0365-5162-X 3-0365-5161-1 Polypharmacy is a necessary and important aspect of drug treatment; however, it becomes a challenge when the medication risks outweigh the benefits for an individual patient. Drug-drug interactions and the introduction of prescribing cascades are common features of polypharmacy, which can lead to ineffectiveness and increased risk of adverse drug reactions (ADR). Genes encoding CYP450 isozymes and other drug-related biomarkers have attracted considerable attention as targets for pharmacogenetic (PGx) testing due to their impact on drug metabolism and response. This Special Issue is devoted to explore the status and initiatives taken to circumvent ineffectiveness and to improve medication safety for polypharmacy patients. Specific areas include drug-drug interactions and consequences thereof in therapeutic management, including PK- and PD-profiling; the application of PGx-based guidance and/or decision tools for drug-gene and drug-drug gene interactions; medication reviews; development and application of deprescribing tools; and drivers and barriers to overcome for successful implementation in the healthcare system.Clinical Utility of Applying PGx and Deprescribing-Based Decision Support in Polypharmacy Manufacturing industriesbicsscMedicine and Nursingbicssc2019 Beers criteria5'nuclease assay80 and overabacaviracute kidney injuryadverse drug reactionadverse drug reactionsagedallopurinolantidepressantsantiepileptic drugsantipsychoticsappropriatenessbleedingchildrenchronicclinical pharmacistclozapineCNVcopy number variationcost-effectivenessCYP1A2CYP2D6CYP2D7PCYP2D8Pcytochrome P450cytochromesdeprescribingdeprescriptionsdeterminantsdigital decision-supportdigital healthDOACsdrug hypersensitivitydrug information servicedrug interaction checkersdrug metabolizationdrug-drug interactionsdrug-gene interactionsearly biomarkerelectronic medical recordelectronic prescribingemergency departmentEthiopiaexosomesextracellular vesiclesflucloxacillingeneral practicegenotypinghealth outcomeshealth services researchhigh resolution meltingHLAhospital pharmacy serviceHRMloxapinemedication adherencemedication optimizationmedication reconciliationmedication reviewmedication-based risk scoremicrovesiclesmultimorbiditynursing homesolanzapineolder adultsolder patientsoutpatientpersonalized medicinepersons with diabetespharmacogene expressionpharmacogeneticspharmacogenomicsphenprocoumonplasma neutrophil gelatinase-associated lipocalinpolypharmacypopulation-basedpotentially inappropriate medication useprevalenceprocess evaluationquality of lifeshared medication recordSLCO1B1soluble urokinase plasminogen activator receptorthromboembolismutilityyouthManufacturing industriesMedicine and NursingVermehren Charlotteedt1296269Westergaard NielsedtVermehren CharlotteothWestergaard NielsothBOOK9910595072903321Clinical Utility of Applying PGx and Deprescribing-Based Decision Support in Polypharmacy3023932UNINA